09:58:00 EDT Mon 15 Jul 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:AWKNF - AWAKN LIFE SCIENCES CORP - https://awaknlifesciences.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AWKNF - Qnot subscribed0.08615    0.26  0.0422Jul 12Jun 0415 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-06-04 07:31U:AWKNFNews ReleaseAwakn Life Sciences Announces Closing of Tranche of Private Placement
2024-05-02 18:01U:AWKNFNews ReleaseAwakn Life Sciences Discusses Filing of Financial Statements
2024-04-17 07:31U:AWKNFNews ReleaseAwakn Life Sciences Announces Closing of Tranche of Private Placement
2024-04-03 07:31U:AWKNFNews ReleaseAwakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
2024-02-12 07:33U:AWKNFNews ReleaseAwakn Life Sciences Announces Listing on the Canadian Securities Exchange
2024-02-05 07:31U:AWKNFNews ReleaseAwakn Life Sciences Announces Conditional Approval of CSE Listing
2024-01-24 07:31U:AWKNFNews ReleaseAwakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
2023-12-20 07:31U:AWKNFNews ReleaseAwakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS
2023-12-15 07:31U:AWKNFNews ReleaseAwakn Life Sciences Provides Corporate Update
2023-11-15 07:31U:AWKNFNews ReleaseAwakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001
2023-11-10 17:01U:AWKNFNews ReleaseAwakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements
2023-10-31 07:31U:AWKNFNews ReleaseAwakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder
2023-10-04 08:31U:AWKNFNews ReleaseAwakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study
2023-09-14 07:31U:AWKNFNews ReleaseAwakn Life Sciences Provides Corporate Update
2023-09-06 07:31U:AWKNFNews ReleaseAwakn Life Sciences Submits Clinical Trial Application for Phase III Trial of AWKN-P001
2023-08-01 07:31U:AWKNFNews ReleaseAwakn Life Sciences Completes Sale of Awakn Clinics In Norway